Intravitreal triamcinolone acetonide as treatment of ischemic ophthalmopathy

Eur J Ophthalmol. 2003 Jul;13(6):575-6. doi: 10.1177/112067210301300611.


Purpose: To describe the clinical course of a patient receiving repeated intravitreal injections of triamcinolone acetonide (25 mg) as treatment of ischemic ophthalmopathy.

Methods: A 70-year-old patient with Waldenström disease presented with progressive iris neovascularization, vitreous hemorrhage, and ocular hypotony due to ischemic ophthalmopathy. Visual acuity was 0.05. Within 2.5 years, he received three intravitreal injections of 25 mg of triamcinolone acetonide. Additionally, penetrating keratoplasty and synechiolysis were performed during the follow-up.

Results: After each intravitreal injection, visual acuity and intraocular pressure increased, iris neovascularization regressed, and vitreous haze cleared up.

Conclusions: Intravitreal triamcinolone acetonide may induce regression of iris neovascularization, increase intraocular pressure, and improve visual acuity in eyes presenting with ocular hypotony, vitreous hemorrhage, and progressive intraocular neovascularization due to ischemic ophthalmopathy.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Anti-Inflammatory Agents / administration & dosage
  • Anti-Inflammatory Agents / therapeutic use*
  • Eye / blood supply*
  • Humans
  • Injections
  • Intraocular Pressure / drug effects
  • Iris / blood supply
  • Ischemia / drug therapy*
  • Male
  • Neovascularization, Pathologic / drug therapy
  • Neovascularization, Pathologic / etiology
  • Ocular Hypotension / etiology
  • Treatment Outcome
  • Triamcinolone Acetonide / administration & dosage
  • Triamcinolone Acetonide / therapeutic use*
  • Visual Acuity
  • Vitreous Body / drug effects
  • Vitreous Hemorrhage / etiology
  • Waldenstrom Macroglobulinemia / complications


  • Anti-Inflammatory Agents
  • Triamcinolone Acetonide